Hinge Health HNGE

Reference table

1. What it is

Hinge Health, Inc. (NYSE: HNGE) operates a digital musculoskeletal (MSK) care platform — app-delivered exercise therapy, wearable motion sensors, and clinical/administrative support spanning general MSK care, acute injuries, chronic pain, and post-operative rehab. Founded 2012, headquartered at 455 Market Street, San Francisco; CEO and co-founder Daniel A. Perez; ~1,514 full-time employees. It listed on the NYSE on 2025-05-22, making it a roughly 13-month-old public company. Fiscal year ends December 31.

Revenue mix — a data caveat, honestly stated: the FMP segment file shows a single reportable segment ($587.9M FY25, i.e., all of revenue) and the geographic segment file is empty. We therefore cannot decompose revenue by product line or geography from this data pull; the business is best understood as one integrated B2B digital-MSK offering sold to employers and health plans (per the company profile). No customer-concentration figures are available in the file — that is a real blind spot, flagged again in §11.

2. The expert thesis (traceable)

No expert-panel coverage — this note is fundamentals-driven. The Synthos KB contains zero claims on HNGE (breadth 0, claim count 0). That is the honest house standard for screen-surfaced names: HNGE entered coverage via the quant momentum screen, not the conviction track, and no voice in the panel has spoken on it. Two consequences, stated plainly:

• No conviction rating can be assigned. There is no high-skill bull (or bear) to weight; both the bull and bear cases in §3 are built entirely from the filed numbers, analyst consensus, and the technical tape.
• The usual corroboration layer is missing. For conviction-track names we can triangulate management's story against independent expert voices. Here the only narrative inputs are the company's own filings and sell-side estimates (15 Buy / 1 Hold — a cheerleading skew worth discounting, especially on a recent IPO where covering banks were often underwriters).

If panel voices pick up HNGE later, this note gets re-versioned with traceable claims.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics:

The three cases (our own scenario model — assumptions labeled; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path; the cases bound the range.

Synthos fair value = the base case, ~$77 (−13%), full range $45–$95. The uncomfortable, honest headline: even the bull case offers only ~+7% from today's $88.52, while the bear case is −49%. That asymmetry — not any defect in the business — is what makes this a Watch. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders from exponentials (accelerating, multi-baggers-from-here). HNGE is fast but decelerating — the price action looks exponential; the estimates do not:

• Forward growth: revenue 2026E $821M → 2030E $1.93B, a ~23.8% CAGR; adjusted EPS 2026E $2.59 → 2030E $6.66, a ~26.6% CAGR. Healthy, real, and clearly slower than the +50.6% just printed.
• Acceleration (the 2nd derivative) is negative: +50.6% (FY25 actual) → +39.7% (2026E) → +25.6% (2027E) → +22.2% (2028E), with a modest 2029E blip to +27.2% before +20.2% in 2030E. This is the profile of a category leader maturing, not an inflection steepening — the direct opposite of what earns an 8.
• Room to run: $6.85B market cap against a large employer/payer MSK opportunity — smallness is genuinely on its side, and a 2× (~$13.7B) is not structurally capped by TAM. The constraint is the growth path, not the market size.
• Reinvestment economics: capex is nearly zero (~0.5% of revenue TTM), FCF/OCF conversion 98% — an extremely asset-light model. The catch: the real "reinvestment" line is stock-based compensation, which ran $643M in FY25 (~109% of revenue) — the growth engine is fueled with equity, and holders pay for it in dilution.
• Estimate-data caveat (honest flag): FMP's forward EBITDA estimates are deeply negative (2026E ~−$385M) while net-income/EPS estimates are strongly positive ($212M / $2.59) — internally inconsistent, most plausibly a data artifact of mixing GAAP-with-SBC cost lines and adjusted EPS. We rely on the revenue and EPS lines (which reconcile with the company's actual beat history) and disregard the estimate-file EBITDA rows.

Exponential Potential: Moderate (6/10). Small enough to multiply, growing fast, cash-generative — but decelerating on every forward year of consensus. Buy it as a growth compounder at the right price, not as an exponential at any price.

5. Financials (real numbers — FMP annual/quarterly)

• Revenue: FY25 $587.9M, +50.6% (FY24 $390.4M, +33.4% on FY23 $292.7M). Growth accelerated into the IPO year — the deceleration is in the forward estimates, not the reported history.
• Quarterly trajectory: Q1'25 $123.8M → Q2 $139.1M → Q3 $154.2M → Q4 $170.7M → Q1'26 $182.3M (+47.2% YoY). Five straight sequential increases.
• Margins: gross 79.8% FY25 / 80.8% TTM — genuinely software-like. GAAP operating income: FY25 −$546.4M, but that is dominated by the IPO quarter (Q2'25 alone: −$580.7M operating, with R&D $280.0M and G&A $251.2M as pre-IPO equity awards hit the P&L). The clean recent run-rate: Q4'25 operating income +$27.3M (16.0% margin) → Q1'26 +$32.1M (17.6% margin). Two consecutive GAAP-profitable quarters (Q1'26 net income $35.1M, diluted EPS $0.41).
• Earnings quality — read carefully. FY25 GAAP net loss −$528.3M (diluted EPS −$5.19) against $643.0M of stock-based compensation in the cash-flow statement; TTM SBC-to-revenue is ~101% and TTM income quality is −0.41. The positive forward EPS the Street quotes ($2.59 2026E) is adjusted; GAAP TTM EPS is −$6.49. Underwrite the cash flow, count the dilution.
• Cash flow: operating CF $171.4M FY25, capex just −$0.7M, FCF $170.7M — a real cash machine trajectory (FY23 −$68.5M FCF → FY24 +$45.2M → FY25 +$170.7M). FCF yield ~3.0% at this price.
• Balance sheet: cash + short-term investments $363.9M plus $113.2M long-term investments; total debt $8.0M (all capital leases) → net cash ~$200M. Deferred revenue $300.9M, up 38% YoY — a healthy forward-billings signal. Current ratio 1.22 (understated in spirit: the biggest current liability is that non-cash deferred revenue). Goodwill + intangibles are modest ($66.6M, ~9% of assets). Accumulated deficit −$1.05B tells the pre-profitability history.

6. Valuation — priced in or room?

The honest frame: you cannot value HNGE on GAAP trailing numbers (TTM P/E is negative; P/B 22.3× is meaningless for an asset-light model), so everything rests on adjusted forward power — and even that is now full. At $88.52: ~34× 2026E adjusted EPS ($2.59) → ~26× 2027E ($3.39) → ~20× 2028E ($4.43) → ~13× 2030E ($6.66); EV/sales 10.3× TTM → ~8.1× 2026E; P/FCF 33×. FMP's letter rating is C (overall 2/5; ROE, ROA, P/E and P/B all score 1/5 on GAAP optics; DCF scores 3/5). The multiple compression path is attractive if estimates hit — but the deceleration means the market's willingness to keep paying 30×+ adjusted EPS is the whole bet. The single most important valuation fact: the stock trades at $88.52 against a Street consensus target of $77.17 (median $77.50, high $95, low $45) — the market has already run past the analysts who are 15-to-1 bullish on it. When a momentum name is above even its fans' targets, the margin of safety is negative by the Street's own math. Not a value entry; a wait-for-the-pullback entry.

7. Technicals (from the tech block)

• Trend: unambiguously up — $88.52 is the 52-week high (0.0% from high, 0.0% max drawdown from peak), +46% above the 50-DMA ($60.44) and +81% above the 200-DMA ($48.91); MACD +7.44.
• Location: +184% off the 52-week low ($31.17) — the stock has nearly tripled, with most of that move in the last quarter (+127% 3-mo).
• Momentum: RSI(14) ~90.0 — extremely overbought, about as stretched as the indicator gets. Historically this is where fast names pause or mean-revert toward the moving averages, though strong trends can stay overbought longer than shorts stay solvent.
• Relative strength: +127% 3-mo vs SPY +14.6% / QQQ +23.6%; +98% 12-mo vs SPY +21.1% / QQQ +31.2% (note: HNGE only listed 2025-05-22, so the "12-mo" window is essentially its whole public life). Massive leadership — and massive banked gains.
• Read: technicals are stretched, not broken. The trend is real, but this is the statistically worst entry posture in the price action: all-time high, RSI 90, 46% above the 50-DMA. A consolidation toward the rising 50-DMA (~$60) or even a garden-variety 20% pullback (~$71 — near our $77 base fair value and the tier trigger at $70) would transform the risk/reward.

8. Moat & competitive position

Hinge Health's moat case rests on B2B distribution and switching costs: multi-year employer/health-plan contracts (visible in the $300.9M deferred-revenue balance, +38% YoY), an integrated clinical + sensor + software stack that is harder to replicate than a wellness app, and 80%+ gross margins suggesting real pricing power in digital MSK. The 98% FCF conversion and near-zero capex say the model scales without capital. But the moat is unproven at this age: digital-health benefits are a competitive, churn-prone category where employers rebid vendors regularly, ROI claims (surgery avoidance) face payer scrutiny, and the single-segment disclosure gives us no visibility into client concentration.

Peer set (FMP-supplied, market cap) — a data caveat first: the supplied list is almost entirely clinical-stage biotech and pharma — Akero $4.5B, Crinetics $4.4B, Dyne $3.8B, Immunovant $7.9B, Indivior $5.0B, Lantheus $6.7B, Oscar Health $8.2B, Praxis $6.6B, Viking $4.5B, GeneDx $2.0B. Apart from Oscar Health (insurance tech) and arguably GeneDx, none of these are business comps for a digital-MSK platform; the relevant cohort (virtual/digital care and benefits platforms) is absent from the file. Judge HNGE against digital-health operating companies, not this cap-matched biotech list — we decline to draw multiple comparisons from it.

9. Management, capital allocation & guidance

• Leadership: co-founder Daniel A. Perez is CEO; co-founder Gabriel Mecklenburg is Executive Chairman. Founder-led, with a dual-class share structure (Class A/B per the Form 4s) — voting control sits with insiders, a governance discount factor.
• Capital allocation: no dividend, no meaningful buyback program visible; FY25 financing shows $265M of stock issuance against $65M repurchased (IPO-year mechanics, including a large −$351M "other financing" line). The real allocation issue is SBC: $643M in FY25 (~109% of revenue) — shareholders are funding growth via dilution. Diluted share count is already drifting (78.0M FY24 → 82.4M diluted in Q1'26). Watch net dilution per year as the key allocation metric.
• Insider activity (the tell to flag): on 2026-07-01 — days ago, at the highs — Exec Chairman Mecklenburg converted 83,334 Class B shares and sold ~82,600 Class A shares in the $82.97–$85.75 range (~$7.0M). CFO James Budge and President James Pursley filings the same day were F-InKind (tax-withholding on vests — routine). One founder monetizing ~$7M after a +184% run is not a red alert (could be 10b5-1 diversification), but selling at the all-time high, above the Street's target is a mild negative signal that rhymes with our Watch verdict.
• Guidance: no management-guidance claims are in our KB and the earnings-call transcript is not in this data pull — an honest gap. What the file does show: four consecutive EPS beats (Q2'25: $0.67 vs $0.09 est; Q3'25: $0.34 vs $0.24; Q4'25: $0.49 vs $0.04; Q1'26: $0.45 vs $0.39) and revenue beats in three of the last four quarters — a management team that sets clearable bars.

10. Catalysts & what to watch

• Next earnings: 2026-08-04 (Q2 2026; Street EPS $0.59, revenue ~$199.9M, implying +43.7% YoY). The key lines: revenue growth vs the deceleration curve, GAAP operating margin (can it hold the 16–18% of the last two quarters?), and net share-count/SBC trajectory.
• The 2027 selling season: employer benefits decisions concentrate in H2 — client wins/losses announced through the fall set the 2027E $1.03B revenue bar.
• Deferred-revenue growth: the cleanest forward-demand signal in the filings ($300.9M, +38% YoY at FY25) — a deceleration here leads a revenue slowdown.
• Lockup/insider-supply dynamics: a May-2025 IPO means insider ownership is large and increasingly free to trade — the 2026-07-01 chairman sale may be the first of a pattern; watch Form 4 cadence.
• Momentum unwind: RSI ~90 at the high; the first close below the 50-DMA (~$60) region on volume would mark the technical regime change — or, for buyers, the pullback zone.

Thesis tripwires (what would change the call): revenue growth printing below ~+35% YoY in 2026; deferred-revenue growth rolling below revenue growth; GAAP operating margin slipping back negative; net dilution running above ~5%/yr; or — on the bullish side — a pullback into the $70 zone with estimates intact, which upgrades this from Watch to an actionable Tactical entry.

11. Key risks

• Entry-point / de-rating risk (the dominant one): all-time high, RSI ~90, 15% above street consensus, 10× EV/S — any disappointment re-rates violently, and the -49% bear case requires nothing exotic, just a growth stumble plus multiple compression.
• SBC and dilution: $643M FY25 stock comp (~109% of revenue) — the adjusted-EPS story ignores a real, recurring cost; if the market re-prices HNGE on GAAP or dilution-adjusted numbers, the multiple math changes materially.
• Deceleration risk: consensus already has growth halving by 2027 (+25.6%); the premium multiple assumes it doesn't halve faster.
• Young-IPO risks: 13 months of public history, dual-class voting control, thin institutional seasoning, unknown lockup-supply overhang, insider selling starting at the highs.
• Competitive/churn risk: employer digital-health benefits are rebid frequently; ROI (surgery-avoidance) claims face payer scrutiny; no client-concentration disclosure in this data pull to size the single-client risk.
• Data blind spots (honest list): no product/geo segmentation (single reportable segment; empty geo file), no earnings-call guidance in the KB, irrelevant FMP peer set, and internally inconsistent forward-EBITDA estimate rows — this note leans on filed financials, EPS/revenue consensus, and the price action.
• No expert corroboration: zero KB claims — there is no independent high-skill voice validating (or attacking) the story; conviction is structurally capped.

12. Verdict, position sizing & monitoring

Watch. Hinge Health is a genuinely good business by the filed numbers — +47–51% revenue growth, 81% gross margin, a real swing to GAAP profitability (Q4'25 and Q1'26), $171M FY25 FCF, ~$200M net cash, and deferred revenue compounding at +38%. On fundamentals alone it would merit a Tactical Buy. What blocks it is everything about the moment: the stock closed at its all-time high with RSI ~90 after a +127% quarter, trades above the Street's own $77 consensus target, the bull case tops out ~+7% while the bear case is −49%, the forward earnings are adjusted-ex-SBC on ~101%-of-revenue stock comp, and the co-founder chairman sold ~$7M of stock this week. Asymmetry that poor at conviction zero (no expert coverage) is a Watch by house rules, not a chase.

• Sizing: none today. If the pullback comes — the ~$70 tier trigger (≈ −21%, near our $77 base fair value and a normal momentum reset) with estimates and deferred-revenue growth intact — enter as a satellite, ~1–2% of the growth sleeve, sized for a young IPO's volatility.
• Monitoring: re-underwrite on the §10 tripwires; formal re-score at the 2026-08-04 Q2 print. This verdict is logged as a tracked Synthos call as of 2026-07-06 at $88.52.
• Single biggest risk: paying peak price at peak momentum for a decelerating grower — the business can execute perfectly and the stock can still give back 20%+ on multiple compression alone.

Provenance & disclosures

• Traceability: 0 KB claims — no expert-panel coverage. This note is fundamentals-driven per the house standard for momentum-screen names; kb_net_conviction is null because there is nothing to aggregate, and no conviction rating is assigned. Fabricated conviction is structurally impossible (claim-ID reconciliation).
• Data as-of: fundamentals 2026-03-31 (Q1 2026, filed 2026-05-07) · estimates & prices 2026-07-06 · expert claims: none. Forward figures are analyst consensus (FMP), labeled as estimates; forward EPS is adjusted (ex-SBC).
• Earnings-quality caveat: FY25 GAAP results carry ~$643M of IPO-era stock-based compensation (TTM SBC ≈ 101% of revenue); GAAP TTM EPS is −$6.49 while consensus forward EPS is adjusted. Underwrite cash flow and dilution, not the adjusted headline.
• Estimate-data caveat: FMP forward EBITDA rows are negative while EPS/net-income rows are positive — internally inconsistent; we rely on the revenue/EPS lines, which reconcile with the company's actual beat history.
• Segment/peer caveats: single reportable segment and an empty geography file — no mix analysis possible; the FMP-supplied peer list is cap-matched biotech, not business comps, and was not used for relative valuation.
• Fair-value anchoring: base case deliberately anchored on the Street's $77.17 consensus target, cross-checked at ~30× 2026E / ~23× 2027E adjusted EPS; bull/bear bound at the Street high/low ($95/$45) with our multiple assumptions labeled in §3.
• Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
• Version: 2026-07-06. Prior versions available via the deep-dive version dropdown ("based on the info at the time").